Evidence map›Paper›PMID 32419064›Full record

ReviewCurrent diabetes reports2020

Economic Simulation Modeling in Type 2 Diabetes.

Rahul S Dadwani, Neda Laiteerapong

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current diabetes reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
3.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Modeling Chronic Kidney Disease in Type 2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022
    Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rahul S DadwaniPritzker School of Medicine, University of Chicago, Chicago, IL, USA.
Neda LaiteerapongSection of General Internal Medicine, University of Chicago, 5841 South Maryland Ave, Chicago, IL, 60637, USA. nlaiteer@medicine.bsd.uchicago.edu.ORCID 0000-0003-0124-4325
University of Chicago · US

Funding

Research Design, Data, and Analytics CoreP30DK092949 · NIDDK · UNIVERSITY OF CHICAGO · PI Ronald T. Ackermann, MARSHALL H CHIN · 2011 to 2026
$10.0M
NIDDK NIH HHS P30 DK092949
6 · The paper itself

Abstract

purpose of reviewThis paper provides an overview of type 2 diabetes economic simulation modeling and reviews current topics of discussion and major challenges in the field. RECENT

findingsImportant challenges in the field include increasing the generalizability of models and improving transparency in model reporting. To identify and address these issues, modeling groups have organized through the Mount Hood Diabetes Challenge meetings and developed tools (i.e., checklist, impact inventory) to standardize modeling methods and reporting of results. Accordingly, many newer diabetes models have begun utilizing these tools, allowing for improved comparability between diabetes models. In the last two decades, type 2 diabetes simulation models have improved considerably, due to the collaborative work performed through the Mount Hood Diabetes Challenge meetings. To continue to improve diabetes models, future work must focus on clarifying diabetes progression in racial/ethnic minorities and incorporating equity considerations into health economic analysis.

Indexed as

Diabetes Mellitus, Type 2Cost-Benefit AnalysisHumansModels, EconomicCost-effectivenessEconomic simulation modelingHealth economic analysisMount Hood Diabetes ChallengeType 2 diabetes

Identifiers

PMID32419064
OpenAlexW3024404794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.